Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 571

1.

HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.

Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, Choi MY, Lee SK, Kil WH, Lee JE, Nam SJ.

Breast Cancer Res Treat. 2013 Jun;139(3):741-50. doi: 10.1007/s10549-013-2570-6. Epub 2013 May 31.

PMID:
23722313
2.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

3.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.

4.

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M, Zhang Q.

Target Oncol. 2014 Dec;9(4):349-57.

PMID:
24233638
5.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

6.

Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.

Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO.

BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.

7.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

8.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
9.

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.

Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P.

Breast. 2014 Oct;23(5):637-43. doi: 10.1016/j.breast.2014.06.011. Epub 2014 Jul 10.

PMID:
25017122
10.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.

11.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
12.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
13.

The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.

Duan XF, Dong NN, Zhang T, Li Q.

Int J Clin Oncol. 2013 Feb;18(1):26-32. doi: 10.1007/s10147-011-0336-x. Epub 2011 Oct 27.

PMID:
22041927
14.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
15.

[Clinicopathologic features and prognosis of triple negative breast cancer].

Zhou T, Yang L, Ma GM, Li CX, Bai Y, Zhao JA, Wang XL, Geng CZ.

Zhonghua Yi Xue Za Zhi. 2009 Aug 25;89(32):2261-4. Chinese.

PMID:
20095338
16.

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.

Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES; Korean Breast Cancer Society.

Breast Cancer Res Treat. 2010 Aug;123(1):177-87. doi: 10.1007/s10549-010-0998-5. Epub 2010 Jun 24.

PMID:
20574671
17.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
18.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
19.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

20.

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen.

BMC Cancer. 2011 Jun 21;11:262. doi: 10.1186/1471-2407-11-262.

Items per page

Supplemental Content

Write to the Help Desk